Terran Biosciences is slowly but surely finding its place in the psychedelics industry. Last week, the company announced a licensing agreement with Big Pharma’s heavy-weight Sanofi (NASDAQ: SNY).
Founded in 2017, Terran has maintained a low profile until recently. In early March, the company bought a portfolio of central nervous system (CNS) assets from Concert Pharmaceuticals (NASDAQ:CNCE), although it wasn’t specified what those assets consisted of, neither by the seller nor the buyer. A few days later, a press release stated that Terran had entered into an exclusive agreement with Columbia University for the rights to the university’s proprietary CNS biomarker platform.
